Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01191801 · ClinicalTrials.gov registry record · Phase 3
Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML
A Phase 3 study, sponsored by Sunesis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 711
- Enrollment target
NCT01191801: Completed Phase 3 study, sponsored by Sunesis Pharmaceuticals.
NCT01191801 is a Phase 3 study that has completed, run by Sunesis Pharmaceuticals. The registered enrollment target is 711 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01191801, a Phase 3 study, has completed, sponsored by Sunesis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 711 participants
- Enrollment target
Study Summary
This study compared treatment groups of patients treated with vosaroxin and cytarabine versus patients treated with placebo and cytarabine.
Primary Outcome
Vosaroxin + cytarabine patient survival versus placebo + cytarabine patient survival
Interventions
- DRUG vosaroxin + cytarabine
- DRUG placebo + cytarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 711 participants |
| Start Date | 2010-12-17 |
| Est. Completion | 2017-03-01 |
| Phase | Phase 3 |
What the finished NCT01191801 record still lists
NCT01191801 is an interventional study that assigns participants to a tested intervention. The registered 711 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which vosaroxin + cytarabine is the first listed.
NCT01191801 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01191801 about?
NCT01191801 is a clinical study titled "Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML". This study compared treatment groups of patients treated with vosaroxin and cytarabine versus patients treated with placebo and cytarabine.
What is the current status of trial NCT01191801?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 711 participants. The study started on 2010-12-17. Estimated completion is 2017-03-01.
What interventions are being tested in trial NCT01191801?
The interventions under investigation include: vosaroxin + cytarabine (DRUG), placebo + cytarabine (DRUG).
Who is sponsoring clinical trial NCT01191801?
This trial is sponsored by Sunesis Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01191801's enrollment target sits among peer trials
711 501st of 2000 higher than 1,499 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06179160 · 710 participants · Phase 1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- NCT06235697 · 710 participants · Phase 3
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
- NCT06470867 · 710 participants · NA
Randomized Controlled Effectiveness Trial of VA S.A.V.E.
- NCT07022483 · 710 participants · Phase 3
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI